UBS Initiates Coverage On Cullinan Therapeutics with Buy Rating, Announces Price Target of $30
Portfolio Pulse from Benzinga Newsdesk
UBS analyst David Dai has initiated coverage on Cullinan Therapeutics (NASDAQ:CGEM) with a Buy rating and set a price target of $30.
October 24, 2024 | 11:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS has initiated coverage on Cullinan Therapeutics with a Buy rating and a price target of $30, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target by a major financial institution like UBS is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100